Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy

  1. Judy B. de Haan
  1. Diabetic Complications Division, Oxidative Stress Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
  1. Corresponding author: Judy B. de Haan, judy.dehaan{at}bakeridi.edu.au.
Diabetes 2011 Nov; 60(11): 2683-2684. https://doi.org/10.2337/db11-1072
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Diabetes is the major cause of chronic kidney disease worldwide (1) with treatment options focused primarily on glucose control, blood pressure, lipid lowering, and the blockade of the renin-angiotensin system (2). However, despite intensive metabolic control and other interventions (3), the unrelenting decline in kidney function means that for many patients the condition progresses to overt kidney failure. This underpins the urgent need for novel approaches to manage the ever-increasing number of patients with diabetes and chronic kidney disease.

One approach that is attracting attention is the use of compounds to bolster the natural cytoprotective responses of the body. The transcription factor NF-E2–related factor 2 (Nrf2), together with its negative regulator, Kelch-like ECH-associated protein 1 (Keap1), is considered one of the most important cellular defense mechanisms to combat oxidative stress (4) with a particular role in the regulation of phase II detoxifying enzymes (Fig. 1). In particular, NADPH quinone oxidoreductase, glutathione S-transferase, heme oxygenase-1, and γ-glutamylcysteine synthetase are well-studied targets of Nrf2 that are upregulated through the antioxidant response element found in the promoters of these genes (5). Therefore, the coordinated upregulation of genes coding for detoxification, antioxidant, and anti-inflammatory regulators is seen as a potential therapeutic strategy to protect against insults such as inflammation and oxidative stress that are known to be enhanced by the diabetic milieu.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Upregulation of phase II detoxifying enzymes by small molecule activators involves activation of the Nrf2-Keap1 pathway. The transcription factor Nrf2 is held in an inactive state in the cytoplasm through its interaction with two molecules of its inhibitory partner, Keap1. Small molecule activators such as ebselen, sulforaphane, and bardoxolone interact with cysteine residues within Keap1 causing its dissociation from Nrf2. Specificity of a class of activator is thought to reside in the cysteine (cys) residue it interacts with. Unbound Nrf2 then translocates into the nucleus where it interacts with antioxidant response elements (AREs) of more than 300 genes. Upregulation of these phase II detoxification enzymes protects the cell against oxidative stress. Identification of clinically relevant small molecule activators of Nrf2 is offering promise as a new avenue for treatment against diseases such as diabetic nephropathy. (Adapted from Jung and Kwak [17].)

It is therefore not surprising that attention has focused on identifying small molecule activators of the Nrf2/Keap1 pathway. Many chemically diverse activators have already been identified (6), including the glutathione peroxidase-1 mimetic ebselen (7), sulforaphane found in cruciferous vegetables (8), caffeic acid phenethylester from the bee product propolis (9), cinnamic aldehyde (found in cinnamon bark), and most recently, bardoxolone methyl (10,11). Many have shown promising actions relevant to diabetes complications. For example, activation of Nrf2 by sulforaphane is able to suppress hyperglycemia-induced oxidative stress and metabolic dysfunction in human microvascular endothelial cells (8). A preclinical study by Zheng et al. (12) published in this edition of Diabetes also demonstrates the potential utility of the Nrf2 agonists, sulforaphane and cinnamic aldehyde, for improving the metabolic profile and reducing renal injury in mice with streptozotocin-induced diabetes. Specifically, this treatment was associated with reduced oxidative stress and attenuated induction of the profibrotic mediator transforming growth factor-β, the growth inhibitory protein p21, and extracellular matrix proteins in the diabetic kidney. Importantly, sulforaphane and cinnamic aldehyde failed to protect against renal injury in diabetic Nrf2 knockout mice, suggesting that their renoprotective actions are specifically mediated via activation of Nrf2. Furthermore, specifically silencing Nrf2 also increased matrix synthesis.

Rather than directly targeting Nrf2, many agonists appear to work by suppressing its endogenous inhibitor, Keap1. Indeed, the study by Zheng et al. (12) showed that the specific silencing of Keap1 using small interfering RNA was able to reduce the expression of transforming growth factor-β and matrix proteins in human renal mesangial cells under both normal and high glucose conditions. However, limited knowledge of the structural biology of Nrf2-Keap1 means that the precise way in which small molecule agents might interact with Keap1 is still to be fully elucidated. One common feature appears to be their reactivity with the sulfhydryl groups of the Keap1 protein. A recent study by Kobayashi et al. (13), using a zebrafish model of a Keap1 mutation, has shown that certain classes of Nrf2 activators display a greater propensity to modify certain sulfhydryl groups within Keap1. In their classification, sulforaphane and several other Nrf2 activators modified Cys151, while the prostaglandin activators required Cys273 for their activation. Hydrogen peroxide, on the other hand, modified multiple cysteine residues of Keap1 (14), suggesting that the specificity of these small molecule activators may reside in the specific modifications of Keap1 cysteine residues. It is likely that more detailed understanding of the molecular interactions between Nrf2-Keap1 and these small molecule activators will pave the way for additional therapeutic interventions.

Beyond actions on renal fibrosis, small molecule activators of Nrf2 may also have direct actions on renal function. In a recently published double-blind, randomized, placebo-controlled trial using the Nrf2 activator, bardoxolone methyl (15), rapid improvements in the estimated glomerular filtration rate have been noted in patients with type 2 diabetes and impaired renal function (estimated glomerular filtration rate 20–45 ml/min/1.73 m2). That these changes were observed within 4 weeks and were largely reversible when the drug was discontinued suggests a direct hemodynamic effect of this strategy. Given that current intervention appears to slow the decline in renal function by less than 1 ml/min/1.73 m2 per year at best (16), sustained improvements with bardoxolone methyl of between 5–10 ml/min/1.73 m2 potentially represent a major advance over standard therapies. Indeed, the result of this clinical trial is encouraging, and it is sure to lead to a flurry of both preclinical and clinic activity to identify additional Nrf2 activators with possibly even greater efficacy, as well as a deeper understanding of the mode of action of this novel class of compound. If similar improvements in kidney function with other novel activators can be reproduced, the strategy of bolstering antioxidant defenses through modulations of Nrf2 will represent a new class of therapy with potentially major advances over conventional therapy (17).

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying original article, p. 3055.

  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Stenvinkel P
    . Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010;268:456–467pmid:20809922
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Mann JF,
    2. Schmieder RE,
    3. McQueen M,
    4. et al.
    ; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–553pmid:18707986
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Navaneethan SD,
    2. Nigwekar SU,
    3. Sehgal AR,
    4. Strippoli GF
    . Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:542–551pmid:19261819
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Kensler TW,
    2. Wakabayashi N,
    3. Biswal S
    . Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89–116pmid:16968214
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Chan K,
    2. Han XD,
    3. Kan YW
    . An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 2001;98:4611–4616pmid:11287661
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Thomas M,
    2. Cooper ME
    . Bardoxolone improves kidney function in patients with type 2 diabetes. Nat Rev Nephrol. In press
  7. ↵
    1. Sakurai T,
    2. Kanayama M,
    3. Shibata T,
    4. et al
    . Ebselen, a seleno-organic antioxidant, as an electrophile. Chem Res Toxicol 2006;19:1196–1204pmid:16978024
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Xue M,
    2. Qian Q,
    3. Adaikalakoteswari A,
    4. Rabbani N,
    5. Babaei-Jadidi R,
    6. Thornalley PJ
    . Activation of NF-E2–related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008;57:2809–2817pmid:18633117
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Lee Y,
    2. Shin DH,
    3. Kim JH,
    4. et al
    . Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol 2010;643:21–28pmid:20599928
    OpenUrlCrossRefPubMed
  10. ↵
    1. Dinkova-Kostova AT,
    2. Liby KT,
    3. Stephenson KK,
    4. et al
    . Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005;102:4584–4589pmid:15767573
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Yates MS,
    2. Tauchi M,
    3. Katsuoka F,
    4. et al
    . Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6:154–162pmid:17237276
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Zheng H,
    2. Whitman SA,
    3. Wu W,
    4. et al
    . Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011;60:3055–3066
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kobayashi M,
    2. Li L,
    3. Iwamoto N,
    4. et al
    . The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 2009;29:493–502
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Holland R,
    2. Hawkins AE,
    3. Eggler AL,
    4. Mesecar AD,
    5. Fabris D,
    6. Fishbein JC
    . Prospective type 1 and type 2 disulfides of Keap1 protein. Chem Res Toxicol 2008;21:2051–2060pmid:18729328
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Pergola PE,
    2. Raskin P,
    3. Toto RD,
    4. et al.
    ; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327–336pmid:21699484
    OpenUrlCrossRefPubMed
  16. ↵
    1. Brenner BM,
    2. Cooper ME,
    3. de Zeeuw D,
    4. et al.
    ; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869pmid:11565518
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Jung KA,
    2. Kwak MK
    . The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 2010;15:7266–7291pmid:11565518
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes: 60 (11)

In this Issue

November 2011, 60(11)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy
Judy B. de Haan
Diabetes Nov 2011, 60 (11) 2683-2684; DOI: 10.2337/db11-1072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Nrf2 Activators as Attractive Therapeutics for Diabetic Nephropathy
Judy B. de Haan
Diabetes Nov 2011, 60 (11) 2683-2684; DOI: 10.2337/db11-1072
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lifting the Veil on the “Phosphate Flush,” a Cryptic Phenomenon of Experimental Pancreatic Islet Physiology
  • Window of Opportunity: Targeting ANGPTL4 Improves Triglyceride Levels in Maternal Obesity During Pregnancy
  • New Antidiabetes Agent Targeting Both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.